SGRY

Surgery Partners, Inc. (SGRY) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Surgery Partners, Inc. owns and operates a national network of surgical facilities, including 148 ambulatory surgery centers (ASCs) and 19 surgical hospitals across 33 states. As of the reporting date, the Company consolidated 127 facilities for financial reporting purposes. The Company operates primarily in partnership with physicians and healthcare systems.

Key Financial Metrics

Note: Net income attributable to Surgery Partners, Inc. reflects the deduction of significant non-controlling interests (NCI). Adjusted EBITDA is a non-GAAP measure.

Material Changes vs. Prior Period

• Revenue Growth: Q2 2024 revenue increased 14.2% year-over-year, driven by a 9.9% increase in days-adjusted same-facility revenue (comprising a 3.9% increase in case volume and 5.7% increase in revenue per case) and the impact of acquisitions.
• Profitability: While consolidated net income decreased due to higher interest expenses and transaction costs, Adjusted EBITDA grew 18.1% to $118.3 million. Operating income declined 13.1% primarily due to increased transaction and integration costs ($19.3M vs $12.0M) and a loss on debt extinguishment ($5.1M).
• Debt Restructuring: The Company issued $800 million in 7.250% senior unsecured notes due 2032 to redeem existing 2025 and 2027 notes. Additionally, the Company refinanced its term loan facility with $1.4 billion in new 2024 Refinancing Term Loans maturing in 2030.
• Acquisitions: The Company acquired a controlling interest in six surgical facilities and several physician practices for $264.6 million in cash consideration during the first half of 2024.

Guidance, Outlook, and Risks

• Liquidity: The Company reported $213.5 million in cash and cash equivalents and $647.8 million in availability under its senior secured revolving credit facility. Management believes current resources are adequate for short-term and long-term liquidity needs.
• Outlook: Management continues to focus on same-facility performance, selective acquisitions, and de novo facility development. No specific forward-looking financial guidance was provided in this text.
• Risks: Key risks include exposure to changes in government and private insurance reimbursement rates, interest rate fluctuations, supply chain issues, and the ability to integrate acquired facilities. The Company noted that recent increases in interest rates and inflation could negatively affect payor mix and patient volumes.
• Unusual Items: The period included a $5.1 million loss on debt extinguishment related to the refinancing of term loans and $19.3 million in transaction and integration costs.

Investor Verification Checklist

• Non-Controlling Interests (NCI): Verify the impact of NCI on net income attributable to common stockholders, which resulted in a net loss for the quarter despite positive consolidated net income.
• Debt Service Capacity: Review the terms of the new $1.4 billion term loan and $800 million notes to assess future interest expense obligations and covenant compliance (Credit Agreement EBITDA).
• Acquisition Integration: Monitor the integration progress of the six facilities acquired in Q2 2024 and the associated $264.6 million cash outlay.
• Payor Mix Trends: Analyze the shift in revenue mix between private insurance (53.2%) and government payors (41.5%) and potential reimbursement rate changes.
• Executive Changes: Note the retirement of Bradley R. Owens, President of the National Group, effective August 31, 2024, and review the associated compensation agreement.